Back grey_arrow_rt.gif
 
 
Entecavir Approved in India
 
 
  "Bristol-Myers launch antiviral drug for chronic Hepatitis B"
 
New Delhi, July. 1 (PTI): Global pharmaceutical and health care company Bristol-Myers Squibb today launched its antiviral drug in India for the treatment of chronic Hepatitis B.
 
The oral antiviral drug Baraclude (entecavir) has been approved by the Drug Controller General of India and would be marketed by the company itself, Bristol-Myers Squibb India Pvt Ltd Medical Director Ajay Tiku told reporters.
 
Priced at Rs 208 for a 0.5 mg tablet, the company has priced the drug lower in India as compared to other markets.
 
"The pricing has been done to make the medicine cost effective for patients in India," he said.
 
Baraclude got USFDA's approval in March last year to be marketed in the US. It has also been launched in Australia, China, Indonesia, Philippines and Singapore this year.
 
About 350 million people worldwide are chronically infected with Hepatitis B, with nearly 36 million people in India or four per cent of the country's population infected with the virus, he said.
 
Currently apart from Baraclude, two other drugs namely Lamivudine and Adefovir are available for treatment of chronic Hepatitis B in the Indian market.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org